<DOC>
	<DOCNO>NCT01602055</DOCNO>
	<brief_summary>The aim study assess bioequivalence 500 mg Azithromycin FC tablet ( Azivol ) produce PT . Novell Pharmaceutical Laboratories , compare reference product Zithromax 500 mg FC tablet produce Pfizer Australia Pty , Ltd</brief_summary>
	<brief_title>A Bioequivalence Study Two Azithromycin Tablet Formulations Indonesian Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy subject , sex , age 18 55 year old Weight normal range accord accept normal value BMI ( 1825 kg/m2 ) Give write informed consent Acceptable medical history physical examination Normal hematology value include hemoglobin , hematocrit , WBC , platelet , WBC differential Normal laboratory test include : Blood urea nitrogen , sGPT , sGOT , alkaline phosphatase , total bilirubin , total protein , fast glucose , albumin creatinine Normal urinalysis result include : specific gravity , color , pH , sugar , albumin , bilirubin , RBC , WBC cast Acceptable electrocardiogram ( ECG ) result Negative result serological test Hepatitis B , Hepatitis C HIV Negative result pregnancy test Smoker alcoholism Pregnant woman nurse mother Have history hepatic , cardiovascular , gastrointestinal renal disease Potentially sensitive azithromycin relate drug Received investigation drug within four week Donation loss 450 mL blood within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>